Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G)

Eur Neurol. 2002;48(4):207-9. doi: 10.1159/000066162.

Abstract

The dopamine transporter (DAT) may play a role in the pathogenesis of Parkinson's disease (PD) because dopamine-specific neurotoxins are taken into dopaminergic nerve terminals via the DAT. A recent study has demonstrated that a DAT polymorphism in exon 9 (1215A/G) is associated with susceptibility to PD. This finding was not replicated by another study, however. Therefore, the significance of this association was tested using a Chinese sample population consisting of 102 PD patients and 174 controls, together with the association for onset age. Comparing the two groups, neither the genotypic (p = 0.272) nor allelic frequencies (p = 0.209) were statistically different. Further, the mean onset age was not significantly different for PD patients comparing the DAT genotypes (p = 0.925). Our findings confirm those of the previous negative report and, taken together, suggest that the DAT polymorphism (1215A/G) does not play a major role in the susceptibility to PD. Other DAT genetic variants, and the association of these variants with PD symptomatology or treatment response, may merit further investigation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age of Onset
  • Aged
  • Chi-Square Distribution
  • Disease Susceptibility
  • Dopamine Plasma Membrane Transport Proteins
  • Exons / genetics
  • Female
  • Gene Frequency
  • Genotype
  • Humans
  • Male
  • Membrane Glycoproteins*
  • Membrane Transport Proteins / genetics*
  • Middle Aged
  • Nerve Tissue Proteins*
  • Parkinson Disease / etiology
  • Parkinson Disease / genetics*
  • Polymorphism, Genetic*

Substances

  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • SLC6A3 protein, human